ustekinumab
janssen
['ustekinumab', 'psoriasis']
congress #eadvcongress | dr. kim papp reported on results from the first 28 weeks of a phase 3 study comparing ustekinumab biosimilar (ct-p43) with reference ustekinumab (ust) in pts with moderate to severe plaque #psoriasis. 
The Psoriasis and Psoriatic Arthritis Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education.